Recent Content
- Tinostamustine named orphan drug for treating malignant gliomas
- New combination therapy approach may improve ovarian cancer care
- FDA approves 1st treatment for high-risk smoldering myeloma
- CAR T-cell therapy candidate yields lasting response in tough lymphoma
- Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- (no title)
- Darzalex Faspro is first FDA-approved therapy for high-risk smoldering multiple myeloma
- Darzalex Faspro is first FDA-approved therapy for high-risk smoldering multiple myeloma
- FDA speeds development of oral pancreatic cancer treatment